|
1) Takano M, Yamamoto M, Xie Y, et al. Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart. 2007; 93: 1533-6
|
|
|
|
2) Takano M, Yamamoto M, Murakami M, et al. Lack of association between large angiographic late loss and low risk of in-stent thrombus. Circ Cardiovasc Intervent. 2008; 1: 20-7
|
|
|
|
|
|
3) Yamamoto M, Okamatsu K, Inami S, et al. Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy. Am Heart J. 2009; 158: 99-104
|
|
|
|
|
4) Yamamoto M, Takano M, Okamatsu K, et al. Relationship between thin cap fibroatheroma identified by virtual histology and angioscopic yellow plaque in quantitative analysis with colorimetry. Circ J. 2009; 73: 497-502
|
|
|
|
|
5) Takano M, Mizuno K, Okamatsu K, et al. Mechanism and structural characteristics of vulnerable plaques: analysis by coronary angio-scopy and intravascular ultrasound. J Am Coll Cardiol. 2001; 38: 99-104
|
|
|
|
|
|
6) Takano M, Yamamoto M, Inami E, et al. Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: do uncovered struts persist？ J Am Coll Cardiol. 2008; 52: 968-9
|
|
|
|
|
|
7) Xie Y, Takano M, Murakami D, et al. Comparison of neointimal coverage by boptical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three mongths after implantation. Am J Cardiol. 2008; 102: 27-31
|
|
|
|
|
|
8) Takano M, Jan IK, Inami S, et al. In vivo comparison of optical coherence tomography and angioscopy for the evaluation of coronary plaque characteristics. Am J Cardiol. 2008: 101: 471-6
|
|
|
|
|
|
9) Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113: 2335-62
|
|
|
|
|
|
10) Ehara S, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001; 103: 1955-60
|
|
|
|
|
|
11) Meisinger C, et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005; 112: 651-7
|
|
|
|
|
|
12) Holvoet P, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998; 98: 1487-94
|
|
|
|
|
|
13) Tajika K, et al. Malondialdehyde-modified low density lipoprotein is a novel marker as instability of coronary plaque: Angioscopic analysis. J Am Coll Cardiol. 2006; 47: 183A
|
|
|
|
|
|
14) Kashiwagi M, Tanaka A, Kitabata H, et al. Relationship between coronary arterial remodeling, fibrous cap thickness and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome. Circ J. 2009; 73: 1291-5
|
|
|
|
|
|
15) Li QX, Fu QQ, Shi SW, et al. Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography. Heart. 2010; 96: 196-201
|
|
|
|
|
|
16) Hayashida K, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation. 2005; 112: 812-8
|
|
|
|
|
|
17) Kume N, et al. Soluble lectine-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome - a pilot study -. Circ J. 2010; 74: 1399-404
|
|
|
|
|
|
18) Brennan ML, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003; 349: 1595-604
|
|
|
|
|
|
19) Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107: 1579-85
|
|
|
|
|
|
20) Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998; 32: 368-72
|
|
|
|
|
|
21) Momiyama Y, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis. 2010; 209: 206-10
|
|
|
|
|
|
22) Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006; 97: 175-80
|
|
|
|
|
|
23) Park JP, et al. Relationship between multiple plasma biomarkers and vulnerable plaque determined by virtual histology intravascular ultrasound. Circ J. 2010; 74: 332-6
|
|
|
|
|
|
24) Heeschen C, et al. (CAPTURE Study Investigators) Pregnancy-associated plasma protein-A in patients with acute coronary syndrome: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005; 45: 229-37
|
|
|
|
|
|
25) Iversen KK, et al. Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome. Am J Cardiol. 2009; 104: 1466-71
|
|
|
|
|
|
26) Heeschen C, et al; CAPTURE Investigators. Prognostic value of placental growth factor in patients with acute chest pain. JAMA. 2004; 291: 435-41
|
|
|
|
|
|
27) Markovic M, et al. Utility of placental growth factor for prediction of 30-day adverse event in emergency department population with non-ST elevation acute coronary syndrome. Clin Lab. 2010; 56: 215-22
|
|
|
|
|
|
28) Morrow DA, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003; 41: 1264-72
|
|
|
|
|
|
29) Jernberg T, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40: 437-45
|
|
|
|
|
|
30) Ogawa A, et al. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J. 2006; 70: 1372-8
|
|
|
|
|
|
31) Hong YJ, et al. Relationship between N-terminal pro-BNP and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis. Coron Artery Dis. 2009; 20: 518-24
|
|
|
|
|
|
32) Thygesen K, et al. Universal definition of myocardial infarction. Eur Heart J. 2007; 28: 2525-38
|
|
|
|
|
|
33) Latini R, et al. Prognostic value of very low plasma concentration of troponin T in patients with stable chronic heart failure. Circulation. 2007; 116: 1242-9
|
|
|
|
|
|
34) Jeremias A, et al. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing perctaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation. 2008; 118: 632-8
|
|
|
|
|
|
35) Omland T, et al. Distribution and determinants of very low levels of cardiac troponin T in patients with stable coronary artery disease: The PEACE trial (abstract). Eur Heart J. 2008; 29 (Abstract Supplement): 202
|
|
|
|
|
|
36) Laufer EM, et al. The extent of coronary atherosclerosis is associated with increasing circukating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol. 2010; 30: 1269-75
|
|
|
|
|
|
37) Uetani T, et al. The association between plaque characterization by CT angiography and post-procedural myocardial infarction in patients with elective stent implantation. JACC Cardiovasc Imaging. 2010; 3: 19-28
|
|
|
|
|
|
38) Hong YJ, et al. Impact of plaque composition on cardiac troponin elevation after percutaneous coronary intervention: an ultrasound analysis. JACC Cardiovasc imaging. 2009; 2: 458-68
|
|
|
|
|
|
39) Aminian A, et al. Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction. Eur J Intern Med. 2009; 20: 527-32
|
|
|
|
|